



POSTER PRESENTATION

Open Access

Adalimumab treatment in Juvenile Idiopathic Arthritis (JIA) patients with special focus on Uveitis

R Joos^{1,3*}, C Wouters², J Dehoorne¹, D Elewaut¹

From 18th Pediatric Rheumatology European Society (PReS) Congress
Bruges, Belgium. 14-18 September 2011

Objectives

We performed an observational study to evaluate the efficacy of adalimumab treatment of uveitis and arthritis in patients with juvenile idiopathic arthritis.

Results

23 JIA patients with polyarticular course (initial diagnosis: 12 oligo, 2 systemic, 2 psoriatic arthritis, 4 ERA and 3 polyarticular) were treated with adalimumab. Uveitis was found in 14 patients. (SoJIA: 2/2; OligoJIA 12/12). The results of the first six months are communicated.

Ocular: During the first six months of adalimumab treatment no new uveitis episodes occurred. In all patients visual acuity was impaired during the active uveitis phase at the start of adalimumab treatment. Some patients (5/14) recovered sight completely, but in the others impairment of visual acuity remained. The anterior chamber cellularity decreased dramatically in the first 8 weeks. Yet in three patients a low number of white blood cells was still seen after 24 weeks.

Articular: the number of active joints ranged from 0 to 5 (mean 1,30, median 2) at start, at 3 months mean = 0,70 and median = 1, range 0 - 4 and at six months mean = 0,22, median 0, range 0 - 2. The number of joints with LOM ranged from 0 - 5 (mean 1,43, median 1) at start, mean 0,91 after 3 months (median 0, range 0 - 5) and mean 0,39 after 6 months (median 0, range 0 - 4).

Conclusion

Despite the limitations of a relatively small patient group adalimumab treatment shows to be beneficial in JIA patients as well on the ocular disease as on the arthritis. Especially for uveitis we need larger long-

term prospective randomized series to draw definite conclusions.

Author details

¹Centre for pediatric rheumatology, Gent, Belgium. ²Dept of pediatrics, Leuven, Belgium. ³Dept of rheumatology, ZNA, Antwerp, Belgium.

Published: 14 September 2011

doi:10.1186/1546-0096-9-S1-P317

Cite this article as: Joos et al.: Adalimumab treatment in Juvenile Idiopathic Arthritis (JIA) patients with special focus on Uveitis. *Pediatric Rheumatology* 2011 **9**(Suppl 1):P317.

Submit your next manuscript to BioMed Central
and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit



* Correspondence: rik.joos@telenet.be

¹Centre for pediatric rheumatology, Gent, Belgium

Full list of author information is available at the end of the article